Loading clinical trials...

Mobile App-Supported HPV and Breast Cancer Awareness Program | Clinical Trials | Clareo Health

COMPLETEDNA

Mobile App-Supported HPV and Breast Cancer Awareness Program

The Impact of a Mobile App-Supported Human Papilloma Virus and Breast Cancer Program on HPV Literacy and Breast Cancer Screening Beliefs

NCT07471113•Ataturk University

View on ClinicalTrials.gov

Summary

The goal of this study is to learn about the impact of a mobile application-supported education program on women's HPV literacy and their beliefs regarding breast cancer screening. The main questions it aims to answer are: * Does a mobile application-supported program increase HPV literacy levels among women? * Does this intervention strengthen women's positive beliefs and attitudes toward breast cancer screening? Researchers will examine how this holistic, health-based intervention changes participants' awareness and screening perspectives. Participants will: * Use a mobile application designed to provide education on HPV and breast cancer * Complete surveys regarding their HPV knowledge and breast cancer screening beliefs before and after the program * Engage with health-related content through the mobile platform for the duration of the study.

Detailed Description

This study aims to evaluate the effect of a mobile application-supported Human Papillomavirus (HPV) and breast cancer program on HPV literacy and breast cancer screening beliefs among women attending primary health care services.

Eligibility

Age

2 - 5 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•-Women aged 30-65 years
•-Literate (able to read and write)
•-Able to understand and speak Turkish
•-Able to use a smartphone
•-Willing to use the mobile application during the study period and consent to data sharing

Exclusion Criteria

•Having undergone regular breast cancer (mammography) and/or cervical cancer (Pap smear/HPV DNA test) screening within the last 3 years, in accordance with national screening guidelines
•Previous diagnosis of any cancer
•Neurological conditions affecting cognitive function (e.g., dementia, Alzheimer's disease) or physical/psychiatric conditions that would seriously limit study participation and mobile app use
•Pregnancy or breastfeeding
•Participation in another health-related research study during the study period

Locations (1)

Atatürk University

Erzurum, Turkey (Türkiye)

Key Dates

Start Date

November 2, 2025

Primary Completion Date

December 25, 2025

Completion Date

January 2, 2026

Last Updated

March 13, 2026

Enrollment

ACTUAL participants

Conditions

Human Papilloma VirusBreast CancerWomen

Interventions

mobile application

BEHAVIORAL

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mobile App-Supported HPV and Breast Cancer Awareness Program

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Effect of Helfer Skin Tap and Cold Application on Pain and Hemodynamics During Vaccination